Vergoeding 2018-2022 voor ATC-subgroep A10BH : Dipeptidylpeptidase-4-remmers
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| A10BH01 Sitagliptine (Januvia ®) | 8.041.000 | 9.659.400 | 10.544.600 | 10.431.900 | 10.629.400 |
| A10BH02 Vildagliptine (Galvus ®) | 1.473.800 | 1.457.200 | 1.431.000 | 1.229.900 | 1.118.300 |
| A10BH03 Saxagliptine (Onglyza ®) | 416.150 | 391.220 | 350.210 | 298.160 | 268.060 |
| A10BH05 Linagliptine (Trajenta ®) | 2.479.000 | 2.905.300 | 3.279.800 | 3.248.800 | 3.416.700 |
| Totaal | 12.409.950 | 14.413.120 | 15.605.610 | 15.208.760 | 15.432.460 |